Literature DB >> 25123560

[Visual diagnosis while performing transurethral resection of bladder tumors: power or myth?].

S Steffens1, A J Schrader, R Lehmann, H Eggers, S Ising, D Pfister, N Riechert-Mühe, A Leitenberger, A Heidenreich, W Thon, A S Merseburger, M A Kuczyk.   

Abstract

INTRODUCTION: The gold standard for diagnosis and immediate therapy of bladder cancer is a transurethral resection (TURB) followed by histopathologic evaluation. The aim of this study was to assess the reliability of visual diagnosis by the operating urologist concerning dignity (malignant/benign) and staging compared to histopathologic evaluation. This is especially crucial since early mitomycin C instillation is based on the urologist's first impression. STUDY DESIGN AND METHODS: This prospective study included 311 cases of TURB from five German institutions. Surgeons were asked to estimate dignity of the neoplasm, tumor stage, and grade according to a standardized questionnaire.
RESULTS: The subjective estimation/visual diagnosis of the operating urologist achieved a sensitivity with respect to identifying malignant tumors as such of 97%, while specificity was only 41%. Accordingly, the positive (PPV) and negative predictive values (NPV) were 76% and 88%, respectively. In general, muscle invasive cancer was predicted more often than confirmed by pathology (PPV 52%). However, whenever muscle invasive cancer was excluded by the urologist, this was confirmed by the pathologist in most the cases (NPV 95%). The educational degree did not influence the reliability and predictive value of visual diagnosis.
CONCLUSION: This study shows that urologists cannot reliably distinguish benign from malignant lesions of bladder mucosa-regardless of their educational degree. A reliable diagnosis of a pathologist is definitely needed to plan final therapeutic steps.

Entities:  

Mesh:

Year:  2014        PMID: 25123560     DOI: 10.1007/s00120-014-3585-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  6 in total

1.  Optimising existing therapeutic strategies for the treatment of non-muscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C.

Authors:  Richard T Bryan
Journal:  Eur Urol       Date:  2012-06-15       Impact factor: 20.096

Review 2.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.

Authors:  Marko Babjuk; Willem Oosterlinck; Richard Sylvester; Eero Kaasinen; Andreas Böhle; Juan Palou-Redorta; Morgan Rouprêt
Journal:  Eur Urol       Date:  2011-03-22       Impact factor: 20.096

Review 3.  [Intravesical therapy of non-muscle invasive bladder tumors].

Authors:  F Vom Dorp; S Tschirdewahn; G Lümmen
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

4.  [Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?].

Authors:  J Hess; S Tschirdewahn; T Szarvas; R Rossi; H Rübben; F Vom Dorp
Journal:  Urologe A       Date:  2011-06       Impact factor: 0.639

5.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.

Authors:  Richard J Sylvester; Willem Oosterlinck; Adrian P M van der Meijden
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

6.  Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder.

Authors:  Harry W Herr; S Machele Donat; Guido Dalbagni
Journal:  J Urol       Date:  2002-09       Impact factor: 7.450

  6 in total
  1 in total

1.  [Non-muscle-invasive high-grade bladder cancer].

Authors:  G Gakis; A Stenzl; T Horn; J E Gschwend; W Otto; M Burger
Journal:  Urologe A       Date:  2015-04       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.